Alcoholic and nonalcoholic stimulation of hepatic cytochrome P450 2E1; biochemical, pharmacological and pathophysiological consequences;Alkoholowa i niealkoholowa stymulacja wa̧trobowego cytochromu P450 2E1; konsekwencje biochemiczne, farmakologiczne i patofizjologiczne

Gastroenterologia Polska

Volumn 12, Issue 5, 2005, Pages 419-429

  Czech, Ewa ^a   Hartleb, Marek ^b  

^a Zaklad Radiodiagnostyki i Medycyny Nuklearnej   (Poland)

^b Klinika Gastroenterologii   (Poland)

Author keywords

Alcohol; CYP2E1; Diabetes; Fatty liver; Hepatotoxicity of drugs; Obesity; Polymorphisms

Indexed keywords

CYTOCHROME P450 2E1; IRON; REACTIVE OXYGEN METABOLITE;

ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; LIVER DISEASE; PATHOPHYSIOLOGY; REVIEW; XENOBIOTIC METABOLISM;

EID: 27644512312     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Chang G., Kam P.: The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia, 1999, 54, 42-50.
2. Lieber C., DeCarli L.: Hepatic microsomal ethanol-oxidizing system. J. Biol. Chem., 1970, 245, 2505-2512.
3. Lieber C.: The unexpected outcomes of medical research: serendipity and the microsomal ethanol oxidizing system. J. Hepatol., 2004, 40, 198-202.
4. Burnett K., Felder M.: Ethanol metabolism in Peromyscus genetically deficient in alcohol dehydrogenase. Biochem. Pharmacol., 1980, 29, 125-130.
5. Glassman E., McLaughlin G., Forman D., Felder M., Thurman R.: Role of alcohol dehydrogenase in the swift increase in alcohol metabolism (SIAM). Biochem. Pharmacol., 1985, 34, 3523-3526.
6. Kato S., Alderman J., Lieber C.: Respective roles of the microsomal ethanol oxidizing system and catalase in ethanol metabolism by deermice lacking alcohol dehydrogenase. Arch. Biochem. Biophys., 1987, 254, 586-591.
7. Johnsrud E.K., Koukouritaki S.B., Divakaran K., Brunengraber L.L., Mines R.N., McCarver D.G.: Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther., 2003, 307, 402-407.
8. Coolier A., Tingle M., Paxton J., Mitchell M., Keelen J.: Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. Hum. Reprod., 2002, 10, 2564-2572.
9. Mines R.N., McCarver D.G.: The ontogeny of human drug-metabolizing enzymes: Phase I oxidative enzymes. J. Pharmacol. Exp. Ther., 2002, 300, 355-360.
10. Pronko P., Bardina L., Satanowskaya V., Kuzmich A., Zimatkin S.: Effect of chronic alcohol consumption on the ethanol- and acetaldehyde-metabolizing systems in the rat gastrointestinal tract. Alcohol Alcohol., 2002, 37, 229-235.
11. Matsumoto H., Fukui Y.: Pharmacokinetics of ethanol: a review of the methodology. Add. Biol., 2002, 7, 5-14.
12. Lieber C.: Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998) - a review. Alcohol. Clin. Exp. Res., 1999, 23, 991-1007.
13. Oneta C.M., Lieber C.S., Li J., Rüttimann S., Schmidt B., Lattmann J., Rosman A.S., Seitz H.K.: Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J. Hepatol., 2002, 36, 47-52.
14. Pöschl G., Seitz H.K.: Alcohol and cancer. Alcohol Alcohol., 2004, 39, 155-165.
15. Badger T., Ronis M., Seitz H., Albano E., Ingelman-Sundberg M., Lieber C.: Alcohol metabolism: role in toxicity and carcinogenesis. Alcohol. Clin. Exp. Res., 2003, 27, 336-347.
16. Caro A.A., Cederbaum A.I.: Oxidative stress, toxicology, and pharmacology of CYP2E1. Ann. Rev. Pharmacol. Toxicol., 2004, 44, 27-42.
17. Oyama T., Matsumoto A., Isse T., Kim Y., Ozaki S., Osaki T., Sugio K., Yasumoto K., Kawamoto T.: Evidence-based prevention (EBP): approach to lung cancer prevention based on cytochrome 1A1 and cytochrome 2E1 polymorphism. Anticancer Res., 2003, 23, 1731-1738.
18. Kukiełka E., Dicker E., Cederbaum A.: Increased production of reactive oxygen species by rat liver mitochondria after chronic ethanol treatment. Arch. Bioch. Biophys., 1994, 309, 377-386.
19. Sergent O., Griffon B., Cillard P., Cillard J.: Alcohol et stress oxydatif. Pathol. Biol., 2001, 49, 689-695.
20. Miñana J.B., Gomez-Cambronero L., Lloret A., Pallardo J.D., Olmo J.D., Escudero A., Rodrigo J.M., Pellin A., Viña J.R., Viña J., Sastre J.: Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology, 2002, 35, 1205-1214.
21. Cederbaum A.: Iron and CYP2E1-dependent oxidative stress and toxicity. Alcohol, 2003, 30, 115-120.
22. Purohit V., Russo D., Salin M.: Role of iron in alcoholic liver disease: introduction and summary of the symposium. Alcohol, 2003, 30, 93-97.
23. Sarich T.C., Adams S.P., Petricca G., Wright J.M.: Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J. Pharmacol. Exp. Ther., 1999, 289, 695-702.
24. Huang Y., Chern H., Wu J., Chang S., Chiang C., Chang F., Lee S.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology, 2003, 37, 924-930.
25. Zand R., Nelson S.D., Slattery J.T., Thummel K.E., Kalhorn T.F., Adams S.P., Wright J.M.: Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin. Pharmacol. Ther., 1993, 54, 142-149.
26. Chien J.Y., Thummel K.E., Slattery J.T.: Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos., 1997, 25, 1165-1175.
27. Desta Z., Soukhova N.V., Flockhart D.A.: Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob. Agents Chemother., 2001, 45, 382-392.
28. Riordan S., Williams R.: Alcohol exposure and paracetamol-induced hepatotoxicity. Add. Biol., 2002, 7, 191-206.
29. Hazai E., Voreczkey L., Monostory K.: Reduction of toxic metabolite formation of acetaminophen. Biochem. Biophys. Res. Commun., 2002, 291, 1089-1094.
30. Neuman M., Shear N., Jacobson-Brown P., Katz G., Neilson H., Malkiewicz I., Cameron R., Abbott F.: CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity. Clin. Biochem., 2001, 34, 211-218.
31. McCarver D., Byun R., Hines R., Hichme M., Wegenek W.: A genetic polymorphism in the regulatory sequence of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol. Appl. Pharmacol., 1998, 152, 276-281.
32. Emery M., Fisher J., Chien J., Kharasch, Dellinger P., Kowdley K., Thummel K.: CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology, 2003, 38, 428-435.
33. Kessova I., Cederbaum A.: CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr. Mol. Med., 2003, 3, 509-518.
34. Shimojo N.: Cytochrome P450 changes in rats with streptozocin-induced diabetes. Int. J. Biochem., 1994, 26, 1261-1268.
35. Wang Z., Hall S., Maya J., Li L., Asghar A., Gorski J.: Diabetes mellitus increases the in vivo activity of cytochroms P450 2E1 in humans. Br. J. Clin. Pharmacol., 2003, 55, 77-85.
36. Leclerq I., Horsmans Y., Desager J.P., Pauwels S., Geubel A.P.: Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity. Br. J. Nutr., 1999, 82, 257-262.
37. Agrawal S., Bronkovsky H.L.: Management of nonalcoholic steatohepatitis. J. Clin. Gastroenterol., 2002, 35, 253-261.
38. Ishii H.: Common pathogenic mechanisms in ASH and NASH. Hepatol. Res., 2004, 28, 18-20.
39. Lieber C.: CYP2E1: from ASH to NASH. Hepatol. Res., 2004, 28, 1-11.
40. Weltman M.D., Farrel G.C., Hall P., Ingelman-Sundenberg M., Liddle C.: Hepatic cytochrome P 450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology, 1998, 27, 128-133.
41. Weltman M.D., Farrel G.C., Liddle C.: Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology, 1996, 111, 1645-1653.
42. Chalasani N., Gorski J.C., Asghar M., Asghar A., Foresman B., Hall S.D., Crabb D.: Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology, 2003, 37, 544-550.
43. Reichard G.A. Jr, Skutches C.L., Hoeldke R.D., Owen O.W.: Acetone metabolism in human during diabetic ketoacidosis. Diabetes, 1986, 35, 668-674.
44. Peng H.-M., Coon M.J.: Regulation of rabbit cytochrome P450 2E1 expression in HepG2 cells by insulin and thyroid hormone. Mol. Pharmacol., 1998, 54, 740-747.
45. Eliasson E., Mkrtchian S., Ingelman-Sundberg M.: Hormone- and substrate-regulated intracellular degradation of cytochrome P450 (2E1) involving MgATP-activated rapid proteolysis in the endoplasmic reticulum membranes. J. Biol. Chem., 1992, 267, 15765-15769.
46. Johansson E., Eliasson E., Ingelman-Sundberg M.: Hormone controlled phosphorylation and degradation of CYP2B1 and CYP2E1 in isolated rat hepatocytes. Biochem. Biophys. Res. Commun., 1991, 174, 37-42.
47. Hoivik D.J., Manautou J.E., Tveit A., Hart S.G., Khairallah E.A., Cohen S.D.: Gender-related differences in susceptibility to acetaminophen-induced protein arylation and nephrotoxicity in CD-1 mouse. Toxicol. Appl. Pharmacol., 1995, 130, 257-271.
48. Adams L.A., Feldstein A., Lindor K.D., Angulo P.: Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology, 2004, 3, 909-914.
49. Morimoto M., Hagbjörk A., Wan Y., Fu C., Clot P., Albano E., Ingelman-Sundberg M., French S.: Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors. Hepatology, 1995, 21, 1610-1617.
50. Haber P., Apte M., Applegate T., Norton I., Korsten M., Pirola R., Wilson J.: Metabolism of ethanol by rat pancreatic acinar cells. J. Lab. Clin. Med., 1998, 132, 294-302.
51. Koop D.R.: Inhibition of ethanol-inducible cytochrome P450 IIE1 by 3-amino-1,2,4-triazole. Chem. Res. Toxicol., 1990, 3, 377-383.
52. Salmela K.S., Tsyrlov I.B., Lieber C.S.: Azide inhibits human cytochrome P-4502E1, 1A2, and 3A4. Alcohol. Clin. Exp. Res., 2001, 25, 253-260.
53. Gebhardt A., Lucas D., Menez J., Seitz H.: Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology, 1997, 26, 957-961.
54. Thornton-Manning J.R., Lilly P.D., Anderson M.E.: Inhibition of CYP2E1 in rat liver microsomes by dichloroethylene isomers. Toxicologist, 1994, 14, 54.
55. Kharasch E., Hankins D., Jubert C., Thummel K., Tarady J.: Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6 and 3A4 activities: evidence for specificity toward P-450 2E1. Drug Metab. Dispos., 1999, 27, 717-723.
56. Martini R., Ingelman-Sundberg M., Murray M.: Pretranslational and posttranslational regulation of rat hepatic CYPs3A2 and 2E1 by sulfiram. Biochem. Pharmacol., 1997, 54, 1323-1329.
57. Navder K.P., Baraona E., Lieber C.S.: Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. J. Nutr., 1997, 127, 1800-1806.
58. Navder K.P., Lieber C.S.: Dilinoleoylphosphatidylcholine is responsible for the beneficial effects of polyenylphosphatidylcholine on ethanol-induced mitochondrial injury in rats. Biochem. Biophys. Res. Commun., 2002, 291, 1109-1112.
59. Agarwal D.: Genetic polymorphism of alcohol metabolizing enzymes. Pathol. Biol., 2001, 49, 703-709.
60. CYP2E1 allele nomenclature (http://www.imm.kise/CYPalleles/cyp2e1.htm
61. Hu Y., Oscarson M., Johansson I., Yue Q.-Y., Dahl M.-L., Tabone M., Arincñ S., Albano E., Ingelman-Sundberg M.: Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol. Pharmacol., 1997, 51, 370-376.
62. Wong N., Rae F., Simpson K., Murray G., Harrison D.: Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. J. Clin. Pathol. Mol. Pathol., 2000, 53, 88-93.
63. Konishi T., Calvillo M., Leng A.-S., Feng J., Lee T., Lee H., Smith J.L., Sial S.H., Berman N., French S., Eysselein V., Lin K.-M., Wan Y.J.Y: The ADH3*2 and CYP2E1 c2 alleles increase the risk of alcoholism in Mexican American men. Exp. Mol. Pathol., 2003, 74, 183-189.
64. Inoue K., Yamazaki H., Shimada T.: Characterization of liver microsomal 7-ethoxycoumarin O-deethylation and chlorzoxazone 6-hydroxylation activities in Japanese and Caucasian subjects genotyped for CYP2E1 gene. Arch. Toxicol., 2000, 74, 372-378.
65. Verlaan M., Te Morsche R., Roelofs H., Laheij R., Jansen J., Peters W., Drenth J.: Genetic polymorphisms in alcohol-metabolizing enzymes and chronic pancreatitis. Alcohol Alcohol., 2004, 39, 20-24.
66. Matthias C., Jahnke V., Jones P.W., Hoban P.R., Alldersea J.E., Worral S.F., Fryer A.A., Strange R.C.: Cyclin D1, glutathione S-transferase and cytochrome P450 genotypes and outcome in patients with upper aerodigestive tract cancers: assesment of importance of individual genes using multivariant analysis. Cancer Epidemiol. Biomarkers. Prev., 1999, 8, 815-823.
67. Monzoni A., Masutti F., Saccoccio G., Bellentani S., Tiribelli C., Giacca M.: Genetic determinants of ethanol-induced liver damage. Mol. Med., 2001, 7, 255-262.
68. Garte S., Gaspari L., Alexandrie A.-K., Ambrosone C., Autrup H., Autrup J.L., Baranova H., Bathum L., Benhamou S., Boffetta P., Bouchardy C., Breskvar K., Brockmoller J., Cascorbi I., Clapper M.L., Coutelle C., Daly A., Dell'Omo M., Dolzan V., Dresler C.M., Fryer A., Haugen A., Hein D.W., Hildesheim A., Hirvonen A., Hsieh L.-L., Ingelman-Sundberg M., Kalina I., Kang D., Kihara M., Kiyohara C., Kremers P., Lazarus P., Le Marchand L., Lechner M.C., van Lieshout E.M.M., London S., Manni J.J., Maugard C.M., Morita S., Nazar-Stewart V., Noda K., Oda Y., Parl F.F., Pastorelli R., Persson I., Peters W.H.M., Rannug A., Rebbeck T., Risch A., Roelandt L., Romkes M., Ryberg D., Salagovic J., Schoket B., Seidegard J., Shields, P.G., Sim E., Sinnet D., Strange R.C., Stucker I., Sugimura H., To-Figueras J., Vineis P., Yu M.C., Taioli E.: Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers. Prev., 2001, 10, 1239-1248.
69. Frenzer A., Butler W., Norton J., Wilson J., Apte M., Pirola R., Ryan P., Roberts-Thomson J.: Polymorphism in alcohol-metabolizing enzymes, glutatione S-transferases and apolipoprotein E and susceptibility to alcohol-induced cirrosis and chronic pancreatitis. J. Gastroenterol. Hepatol., 2002, 17, 177-182.
70. Hamdy I., Hiratsuka M., Narahara K., El-Enany M., Moursi N., Ahmed M., Mizugaki M.: Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharmacol., 2002, 53, 596-603.
71. Nishimoto I.N., Hanaoka T., Sugimura H., Nagura K., Ihara M., Li X., Arai T., Hamada G., Kowalski L., Tsugane S.: Cytochrome P450 2E1 polymorphism in gastric cancer in Brazil: case-control studies of Japanese Brazilians and non-Japanese Brazilians. Cancer Epidemiol. Biomarkers. Prev., 2000, 9, 675-680.
72. Gao C., Takezaki T., Wu J., Li Z., Wang J., Ding J., Liu Y., Hu X., Xu T., Tajima K., Sugimura H.: Interaction between cytochrome P450 2E1 polymorphisms and enviromental factors with risk of esophageal and stomach cancers in Chinese. Cancer Epidemiol. Biomarkers. Prev., 2002, 11, 29-34.
73. Tan W., Wu J., Tang H., Lin D.: Expression of cytochrome P4502E1 in human liver: relationship between genotype and phenotype in Chinese. Sci. China, 2001, 44, 356-364.
74. Wu R., Cheng C., Chen K., Shan D., Kuo J., Ho Y., Chern H.: Genetic polymorphism of CYP2E1 gene and susceptibility to Parkinson's in Taiwanese. J. Neural. Transm., 2002, 109, 1403-1414.
75. Le Marchand L., Wilkinson G., Wilkens L.: Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol. Biomarkers. Prev., 1999, 8, 495-500.
76. Choi J.-Y., Abel J., Neuhaus T., Ko Y., Harth V., Hamajima N., Tajima K., Yoo K.-Y., Park S., Noh D.-Y., Han W., Choe K.J., Ahn S.-H., Kim S.-U., Hirvonen A., Kang D.: Role of alcohol and genetic polymorphisms of CYP2E1 and ALDH2 in breast cancer development. Pharmacogenetics, 2003, 13, 67-72.
77. Choi J.Y., Lee S.M., Cho S.H., Choi H.N., Lee S.Y., Im H.J., Yoon K.J., Choi H., Choi I., Hirvonen A., Hayes R., Kang D.: CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics, 2003, 13, 349-355.
78. Park G., Lee O., Kwon S., Lee C., Yoon B., Hahm J., Lee M., Lee D., Kee C., Sun H.: Gastic cancer: genetic suscebtibility. Analysis of CYP2E1 polymorphism for the determination of genetic susceptibility to gastric cancer in Koreans. J. Gastroenterol. Hepatol., 2003, 18, 1257-1263.
79. Stephens E.A., Taylor J.A., Kaplan Y., Yang C.H., Hsieh L.L., Lucier G.W., Bell D.A.: Ethnic variation in CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics, 1994, 4, 185-192.
80. Wan Y.-J., Poland R., Lin K.-M.: Genetic polymorphism of CYP2E1, ADH2, and ALDH2 in Mexican-Americans. Genet. Test., 1998, 2, 79-83.
81. Howard L., Ahluwalia J., Lin S.-K., Sellers E., Tyndale R.: CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics, 2003, 13, 321-328.
82. Hildesheim A., Anderson L., Chen C. J., Cheng Y.-J.: CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J. Natl. Cancer Inst., 1997, 89, 1207-1212.
83. Sun F., Tsuritani I., Yamada Y.: Contribution of genetic polymorphisms in ethanol-metabolizing enzymes to problem of drinking behavior in middle-aged Japanese men. Behav. Genet., 2002, 32, 229-236.
84. Nakamura K., Iwahashi K., Ameno K., Sekine Y., Suzuki K., Mori N.: CYP2E1 and clinical features in alcoholics. Neuropsychobiology, 2003, 47, 86-89.
85. Yamada Y., Sun F., Tsuritani I., Honda R.: Genetic differences in ethanol metabolizing enzymes and blood pressure in Japanese alcohol consumers. J. Hum. Hypertens., 2002, 16, 479-486.
86. Halsted C.H., Villanueva J.A., Devlin A.M.: Folate deficiency, methionine metabolism and alcoholic liver disease. Alcohol, 2002, 27, 169-172.
87. Lieber C.: Alcohol and the liver: metabolism of alcohol and its role in hepatic and extrahepatic disease. Mt Sinai J. Med., 2000, 67, 84-94.
88. Lieber C.: Alcoholic liver injury: pathogenesis and therapy in 2001. Pathol. Biol., 2001, 49, 738-752.
89. Lieber C.: New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr. Gastroenterol. Rep., 2004, 6, 60-65.
90. Parlesak A., Billinger M., Bode C., Bode J.: Gastric alcohol dehydrogenase activity in man: influence of gender, sex, alcohol consumption and smoking in a Caucasian population. Alcohol Alcohol., 2002, 4, 388-393.
91. Song Z., Joshi-Barve S., Barve S., McClain C.: Advances in alcoholic liver disease. Curr. Gastroenterol. Rep., 2004, 6, 71-76.
92. Stewart S., Day C.: The management of alcohol liver disease. J. Hepatol., 2003, 38, S2-S13.
93. Chao Y.-C., Young T.-H., Tang H.-S., Hsu C.-T.: Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patiens. Hepatology, 1997, 25, 112-117.
94. Munaka M., Kohsi K., Kawamoto T., Takasawa S., Nagata N., Itoh H., Oda S., Katoh T.: Genetic polymorphisms of tabacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol., 2003, 129, 355-360.